Stock Events

Qiagen NV 

$43.54
46
-$0.81-1.83% Today

Statistics

Day High
44.14
Day Low
43.41
52W High
47.44
52W Low
34.74
Volume
1,671,621
Avg. Volume
1,276,828
Mkt Cap
10.16B
P/E Ratio
130.6
Dividend Yield
3.03%
Dividend
1.32

Upcoming

Dividends

3.03%Dividend Yield
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

30OctExpected
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
Q2 2024
Next
0.44
0.49
0.54
0.59
Expected EPS
0.544371
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow QGEN. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Illumina
ILMN
Mkt Cap20.93B
Illumina provides sequencing and array-based solutions for genetic analysis, directly competing in the genomics space with Qiagen's sample and assay technologies.
Thermo Fisher Scientific
TMO
Mkt Cap234.95B
Thermo Fisher Scientific offers a broad range of reagents, instruments, and consumables used in biological and medical research, competing with Qiagen in multiple areas including sample preparation and diagnostics.
Bio-Rad Laboratories
BIO
Mkt Cap9.35B
Bio-Rad Laboratories offers products and systems used to separate complex chemical and biological materials, directly competing with Qiagen in the life sciences research market.
Agilent Technologies
A
Mkt Cap41.06B
Agilent Technologies provides instruments, services, consumables, applications, and expertise, focusing on the life sciences, diagnostics, and applied chemical markets, competing with Qiagen in diagnostics and research.
Pacific Biosciences of California
PACB
Mkt Cap373.36M
Pacific Biosciences offers sequencing systems that compete with Qiagen's genomic and DNA sequencing solutions.
Repligen
RGEN
Mkt Cap8.45B
Repligen Corporation provides bioprocessing technologies and systems that compete with Qiagen's solutions for the purification and isolation of biological samples and substances.
Bio-Rad Laboratories
BIO.B
Mkt Cap8.84B
Bio-Rad Laboratories, through its Class B shares, competes in the same space as its Class A shares, offering similar products and technologies that rival Qiagen's offerings.
Hologic
HOLX
Mkt Cap18.87B
Hologic specializes in diagnostics, medical imaging systems, and surgical products, competing with Qiagen in the diagnostics and women's health market.
Quest Diagnostics
DGX
Mkt Cap17.47B
Quest Diagnostics provides diagnostic testing, information, and services, competing with Qiagen in the diagnostics and molecular diagnostics markets.
Guardant Health
GH
Mkt Cap3.15B
Guardant Health focuses on liquid biopsies and cancer diagnostics, competing with Qiagen in the precision medicine and cancer diagnostics space.

Analyst Ratings

50.25$Average Price Target
The highest estimate is $54.
From 4 ratings within the last 6 months. This is not an investment recommendation.
Buy
75%
Hold
25%
Sell
0%

About

Health Technology
Medical Specialties
Manufacturing
Biological Product (except Diagnostic) Manufacturing
QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV, as well as assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. In addition, it offers PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping, and gene regulation instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR solutions; and developed and configured OEM consumables. Further, the company provides predefined and custom NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments, as well as bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. It has a strategic alliance agreement with Sysmex Corporation and OncXerna Therapeutics, as well as an agreement with Mirati. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.
Show more...
CEO
Thierry Bernard
Employees
5900
Country
NL
ISIN
NL0015001WM6

Listings